PERI-EDU University Education
Cardiovascular disease, obesity and metabolic syndrome can coexist with peri-implant disease through shared biological, behavioural and social pathways. Current evidence does not establish that one condition directly causes the other or that peri-implant treatment prevents cardiovascular events. Clinical care should combine accurate local diagnosis with assessment of systemic stability, medication and procedural risk.
Cardiometabolic multimorbidity in implant care
Cardiovascular disease includes coronary, cerebrovascular, peripheral vascular and heart conditions with different causes and clinical implications. Obesity describes excess or dysfunctional adipose tissue that may impair health. Metabolic syndrome identifies a cluster involving central adiposity, dysglycaemia, raised blood pressure, high triglycerides and low HDL cholesterol.
| Clinical context | What it describes | Why it matters |
|---|---|---|
| Cardiovascular disease | A broad group including atherosclerotic disease, heart failure and arrhythmias. | Stability, functional capacity, medication and recent events may affect procedural safety. |
| Obesity | A chronic disease involving excess or dysfunctional adipose tissue; BMI does not directly measure visceral fat. | Ergonomics, access, comorbidity and maintenance delivery may require adaptation. |
| Metabolic syndrome | A constellation of metabolic and cardiovascular risk components. | Components cluster and confound one another; definitions differ among authorities. |
| Multimorbidity | Multiple chronic conditions, often with several medicines and care teams. | The combined burden matters more than one diagnostic label. |
Shared pathways do not establish shared causation
Peri-implantitis is a plaque-associated inflammatory condition. Cardiometabolic diseases also involve inflammatory, vascular and metabolic pathways. Parallel biology can make an association plausible, but plausibility alone cannot establish direction, independence or clinical magnitude.
- Low-grade inflammation: several tissues can contribute to circulating mediators, so a systemic marker cannot identify its source.
- Vascular function: impaired perfusion may influence repair, but a cardiovascular diagnosis does not prove impaired healing at one implant site.
- Insulin resistance: altered immune and bone-cell responses may modify susceptibility; diabetes control still requires separate assessment.
- Behavioural and social exposure: smoking, diet, maintenance attendance and access to care may affect both groups of conditions.
Plaque, prosthetic cleansability, implant position, tissue conditions and supportive care remain central. Cardiometabolic disease cannot explain bleeding, suppuration or bone loss without clinical and radiographic evaluation.
Cardiovascular disease: association remains uncertain
A 2023 meta-analysis of five observational studies reported a small association between cardiovascular disease and peri-implantitis. The 2025 AO/AAP systematic review found heterogeneous cardiovascular definitions, few cross-sectional studies and insufficient comparable data for meta-analysis. The newer synthesis therefore supports cautious interpretation.
| Evidence question | Current interpretation | Reason for caution |
|---|---|---|
| Do the conditions coexist? | Some observational studies report associations. | Definitions range from hypertension to atherosclerosis and broad cardiovascular disease. |
| Is the association independent? | Uncertain. | Age, smoking, diabetes, periodontitis and socioeconomic conditions may affect both outcomes. |
| Which condition comes first? | Usually unresolved. | Cross-sectional studies cannot establish temporality. |
| Does peri-implant treatment improve cardiovascular outcomes? | No demonstrated clinical benefit. | Intervention studies with cardiovascular endpoints are lacking. |
Peri-implant therapy aims to control local disease and preserve implant support. It should not be presented as a method for preventing myocardial infarction, stroke or another cardiovascular event.
Obesity and peri-implant outcomes
A 2026 systematic review and meta-analysis found no statistically significant difference in implant failure between groups with and without obesity. Pooled analyses showed less favourable plaque, bleeding, probing depth and marginal bone measures in obesity. However, certainty was very low, heterogeneity was high, and the included studies did not provide adjusted outcome estimates.
Most studies used BMI, which can misclassify adiposity and provides limited information about visceral fat or metabolic health. Current evidence does not support denying implant care on BMI alone. Weight-neutral communication and individualized monitoring are appropriate.
Metabolic syndrome as a constellation
Metabolic syndrome combines central adiposity, dysglycaemia, blood-pressure abnormalities and dyslipidaemia. Individual components may influence each other and may also confound associations with peri-implant disease. Direct syndrome-specific evidence remains sparse.
Medical definitions and thresholds vary. Dental teams should record an established diagnosis and its individual components rather than creating a peri-implant-specific metabolic syndrome threshold.
Reading association studies correctly
- Check phenotype definitions: cardiovascular disease, obesity and peri-implantitis must be defined clearly.
- Identify the unit of analysis: multiple implants in one patient are not independent observations.
- Establish temporality: cross-sectional coexistence cannot show which condition came first.
- Review confounder adjustment: smoking, diabetes, periodontitis, age, plaque and maintenance may affect both outcomes.
- Look for longitudinal measurements: systemic and oral exposures can change during follow-up.
- Separate association from treatment benefit: biological plausibility does not prove that modifying one condition improves the other.
Pre-operative assessment and procedural safety
| Domain | Document | Clinical response |
|---|---|---|
| Specific diagnoses | Coronary or cerebrovascular disease, arrhythmia, heart failure, hypertension, obesity, diabetes and sleep-disordered breathing. | Plan according to the actual condition and its stability. |
| Recent clinical course | Hospital admission, acute cardiovascular event, new chest symptoms, breathlessness, syncope or major treatment change. | Postpone elective invasive care and seek medical assessment when instability is suspected. |
| Functional capacity | Tolerance of ordinary activity, positioning and appointment duration. | Adapt chair position, treatment length and staging. |
| Oral risk | Periodontitis, plaque, infection, prosthetic access and maintenance history. | Control active disease before elective implant placement. |
Medical consultation should answer a focused question about stability, recent events, medication and monitoring. New chest pain, breathlessness at rest, syncope, decompensated heart failure or another sign of acute instability requires prompt medical evaluation rather than routine elective treatment.
Medication review
Cardiometabolic treatment commonly involves antiplatelet or anticoagulant medicines, antihypertensives, lipid-lowering agents and glucose-lowering therapy. The medication list may affect bleeding management, postural tolerance, salivary symptoms, drug interactions and appointment planning.
- Do not stop antiplatelet or anticoagulant therapy without a case-specific coordinated plan.
- Use current procedure-specific guidance and local haemostatic measures.
- Change chair position gradually when postural symptoms are possible.
- Follow the patient-specific meal and medication plan when hypoglycaemia is a concern.
- Check interactions before dental prescribing in patients taking multiple medicines.
Antithrombotic therapy can influence bleeding expression, but it does not create or exclude peri-implantitis without the accompanying clinical and radiographic findings.
Integrated prevention and supportive care
Local biofilm control protects peri-implant tissues, while smoking cessation, blood-pressure care and metabolic control have established general-health value. Each intervention should be justified by its own evidence.
| Care component | Action | Claim boundary |
|---|---|---|
| Local disease control | Treat periodontitis and peri-implant disease according to diagnosis. | The goal is control of local inflammation and preservation of support. |
| Prosthetic access | Provide cleansable contours and access for examination. | Systemic optimization cannot correct an inaccessible restoration. |
| Risk-factor support | Encourage smoking cessation, glycaemic care and adherence to cardiovascular treatment. | The dental team supports medical goals rather than prescribing cardiometabolic treatment. |
| Maintenance | Set recall from combined local, metabolic, behavioural and prosthetic risk. | No single diagnosis dictates a universal interval. |
Clinical synthesis
- Identify exact cardiometabolic diagnoses, current stability, medication and complications.
- Separate biological plausibility, observational association and demonstrated causation.
- Do not use BMI, cardiovascular diagnosis or a systemic biomarker as a stand-alone implant eligibility rule.
- Control local plaque-associated disease and maintain access for hygiene and professional care.
- Do not interrupt cardiometabolic medication without an individualized coordinated plan.
- Explain that peri-implant treatment targets local disease and has no established cardiovascular preventive effect.
Download the full educational material
The full PDF includes the biological framework, evidence appraisal, obesity and metabolic syndrome interpretation, pre-operative assessment, medication considerations and a coordinated supportive-care pathway.
Download the full educational material (PDF)
Selected references
- Herrera D, Berglundh T, Schwarz F, et al. Prevention and treatment of peri-implant diseases: the EFP S3 level clinical practice guideline. Journal of Clinical Periodontology. 2023;50(Suppl 26):4-76. doi:10.1111/jcpe.13823.
- Galarraga-Vinueza ME, Pagni S, Finkelman M, Schoenbaum T, Chambrone L. Prevalence, incidence, systemic, behavioral, and patient-related risk factors and indicators for peri-implant diseases. Journal of Periodontology. 2025;96:587-633. doi:10.1002/JPER.24-0154.
- Ye M, Wu Z, Lin X, et al. Impact of obesity on dental implant failure and peri-implant health. BMC Oral Health. 2026;26:515. doi:10.1186/s12903-026-07908-4.
- Chu D, et al. Association between cardiovascular diseases and peri-implantitis. Reviews in Cardiovascular Medicine. 2023;24:200. doi:10.31083/j.rcm2407200.
- Papi P, et al. Peri-implant diseases and metabolic syndrome components: a systematic review. 2018. PMID: 29509232.
- Ustaoglu G, et al. Association between peri-implantitis and systemic inflammation: a systematic review. 2023. PMID: 37691939.
Explore related PERI-EDU resources
#UniversityEducation #OnlineCourses #ClinicalCases #PERIEDU #CardiometabolicHealth #Obesity #MetabolicSyndrome #ImplantCare
This educational material does not replace individualized cardiovascular assessment, medication management, emergency protocols or procedure-specific clinical guidance.
This work was co-funded by the European Union under grant agreement No. 2024-1-PL01-KA220-HED-000251208. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System (FRSE). Neither the European Union nor FRSE can be held responsible for them.